08.19.15
Actinium Pharmaceuticals Inc., a biopharmaceutical company developing immunotherapeutics for advanced cancers, has appointed Felix Garzon senior vice president, head of clinical development. Dr. Garzon brings with him 28 years of pharmaceutical and biotechnology experience in increasingly senior roles, most recently at Eisai and Bristol-Myers Squibb, having worked on both later and earlier stages of drug development.
"I am very excited to join the Actinium organization," said Dr. Garzon. "Actinium is pursuing breakthroughs in the field in which I have more than a quarter of a century of professional experience. With two very promising products poised to enter Phase 3 and Phase 2 trials, I am thrilled to have an opportunity to maximize the development prospects for Iomab-B and Actimab-A.”
Dr. Garzon has more than 28 years of international experience working in positions of increasing responsibility in the development of new oncology and hematology drugs in several successful companies in the United States and Europe. He has successfully led and managed the late development and approval of several anticancer drugs, including Halaven, Trisenox and Xyotax.
Dr. Garzon was previously senior director, oncology product creation unit at Eisai, and director, oncology global clinical research at Bristol-Myers Squibb.
"I am very excited to join the Actinium organization," said Dr. Garzon. "Actinium is pursuing breakthroughs in the field in which I have more than a quarter of a century of professional experience. With two very promising products poised to enter Phase 3 and Phase 2 trials, I am thrilled to have an opportunity to maximize the development prospects for Iomab-B and Actimab-A.”
Dr. Garzon has more than 28 years of international experience working in positions of increasing responsibility in the development of new oncology and hematology drugs in several successful companies in the United States and Europe. He has successfully led and managed the late development and approval of several anticancer drugs, including Halaven, Trisenox and Xyotax.
Dr. Garzon was previously senior director, oncology product creation unit at Eisai, and director, oncology global clinical research at Bristol-Myers Squibb.